Inhalation Aerosols: Physical and Biological Basis for Therapy, Third Edition, 3rd Edition (Hardback) book cover

Inhalation Aerosols

Physical and Biological Basis for Therapy, Third Edition, 3rd Edition

Edited by Anthony J. Hickey, Heidi M. Mansour

CRC Press

417 pages | 55 Color Illus. | 46 B/W Illus.

Purchasing Options:$ = USD
Hardback: 9781138064799
pub: 2019-03-25
Available for pre-order
$169.95
x


FREE Standard Shipping!

Description

Inhalation aerosols continue to be the basis for successful lung therapy for several diseases, with therapeutic strategies and the range of technology significantly evolving in recent years.

In response, this third edition takes a new approach to reflect the close integration of technology with its application. After briefly presenting the general considerations that apply to aerosol inhalation, the central section of the book uses the focus on disease and therapeutic agents to illustrate the application of specific technologies.

The final integrated strategies section draws the major points from the applications for disease targets and drug products.

Table of Contents

0. Introduction

Anthony J. Hickey and Heidi M. Mansour

Section 1 Fundamentals

  1. Physicochemical Properties of Respiratory Particles and Formulations
  2. B. Shekunov

  3. Particle Deposition in the Respiratory Tract and the Effect of Respiratory Disease
  4. Dr. William Bennett

  5. Mathematical Modeling of Inhaled Therapeutic Aerosol Deposition in the Respiratory Tract
  6. Jeffry Schroeter, Bahman Asgharian, and Julia Kimbell

  7. Lung transporters & absorption mechanisms in the lungs.
  8. Mohammed Ali Selo,, Hassan H. A. Al-Alak, Carsten Ehrhardt

  9. Bioavailability of inhaled compounds.
  10. L. Garcia-Contreras

  11. 3D models as tools for inhaled drug development.
  12. Sally-Ann Cryan, Jennifer Lorigan, Cian O’Leary

  13. Overview of the delivery technologies for inhalation aerosols
  14. Daniel F. Moraga-Espinosa, Ashlee D. Brunaugh, Silvia Ferrati, Lara A. Heersema, Matthew J. Herpin, Patricia P. Martins, Hairui Zhang, Hugh D. C. Smyth

    Section 2 Applications, Influence of Lung Disease Pathophysiology on Aerosol Deposition, Inhaler Device Technique in Respiratory Disease, & Clinical Outcomes in Drug Performance Assessment

  15. Neonatal & Pediatric Inhalation Drug Delivery
  16. Ariel Berlinski

  17. Asthma
  18. Omar Usmani

  19. Drug Delivery in Pulmonary Aspergillosis
  20. Sawittree Sahakijpijarn, Jay I. Peters, Robert O. Williams III

  21. Lung Cancer Inhalation Therapeutics
  22. Rajiv Dhand

  23. Inhaled Therapeutics in Chronic Obstructive Pulmonary Disease
  24. Tejas Sinha, Paul DeJulio and Philip Diaz

  25. Cystic fibrosis infection & Biofilm Busters
  26. Jennifer Fiegel and Sachin Gharse

  27. CURRENT AND FUTURE CFTR Therapeutics-
  28. Marne C. Hagemeijer, Gimano D. Amatngalim and Jeffrey M. Beekman

  29. Innate and Adaptive Barrier Properties of Airway Mucus
  30. Alison Schaefer, Samuel K. Lai

  31. Non-tuberculous mycobacteria (NTM)
  32. M. Ghadiri, P. M. Young, and D. Traini

  33. Inhalational Therapies for Non-CF Bronchiectasis
  34. Ashvini Damodaran, Dustin R. Fraidenburg, and Israel Rubinstein

  35. Pulmonary Fibrosis,
  36. Priya Muralidharan, Dr. Don Hayes, Jr, and Dr. Heidi M. Mansour

  37. Therapeutics in Pulmonary Hypertension
  38. Maria F. Acosta, Don Hayes, Jr., Jeffrey R. Fineman, Jason X.-J. Yuan, Stephen M. Black, and Heidi M. Mansour

  39. Respiratory distress syndrome,
  40. Heidi M. Mansour, Debra Droopad, and Julie G. Ledford

  41. Surfactant Aerosol Therapy for nRDS and ARDS
  42. Donovan B. Yeates

  43. Fundamentals in Nasal Drug Delivery
  44. Zachary Warnken, Yu jin Kim, Heidi M. Mansour, Robert O. Williams III, Hugh D.C. Smyth

  45. Inhaled therapeutics against TB: the promise of pulmonary treatment and prevention strategies in the clinic
  46. Dominique N; Kunda, Nitesh K. Miller, Elliott K.; Muttil, Pavan

    Section 3 Integrated strategies (reflecting combined elements from chapters 8-23):

  47. Inhaled medication: factors that affect lung deposition
  48. Joy Conway

  49. A Critical Perspective on Future developments based on the knowledge we have now

Tania F. Bahamondez-Canas, Jasmim Leal, Hugh D.C. Smyth

26. Ensuring Effectiveness and Reproducibility of Inhaled Drug Treatment

Anthony J Hickey

27. Conclusion

A.J. Hickey, and H.M. Mansour

About the Editors

Dr. Heidi M. Mansour, Ph.D., R.Ph. is a Tenured Associate Professor of Pharmaceutical Sciences in the College of Pharmacy with joint faculty appointments in the BIO5 Research Institute and the College of Medicine in the Division of Translational and Regenerative Medicine at The University of Arizona (UA) in Tucson, Arizona (USA). Dr. Mansour has faculty member affiliations in the UA Institute of the Environment, and the UA NCI Comprehensive Cancer Center. She lectures in the B.S. Pharmaceutical Sciences undergraduate program, the Pharm.D. professional program and in the Pharmaceutics and Pharmacokinetics track of the graduate program at The University of Arizona. In addition to teaching, Dr. Mansour serves as Faculty Advisor in the Pharm.D./Ph.D. Dual-Degree Joint Program and Director of the Pharmaceutics and Pharmacokinetics track in the Pharmaceutical Sciences graduate program in The UA College of Pharmacy. Dr. Mansour has published over 80 peer-reviewed scientific journal papers, 9 book chapters, 2 edited books, and over 100 scientific conference abstracts. She serves on the Editorial Advisory Boards of the The Royal Society of Chemistry Molecular Systems Design & Engineering, APhA/FIP Journal of Pharmaceutical Sciences, and Pharmaceutical Technology.

Dr. Mansour is an annual Faculty Instructor at ISAM (International Society of Aerosols in Medicine) Aerosol School, instructor in two online webinars on inhalation aerosol drug delivery, and instructor in Buchi Advanced Spray Drying short-courses. She was recently Co-Chair of the Drug Delivery: New Devices & Emerging Therapies Group in the International Society of Aerosols in Medicine (ISAM), and has been an expert member of NIH NICHD U.S. Pediatric Formulations Initiative New Drug Delivery Systems Aerosols Working Group for several years. Dr. Mansour currently serves on the Drug/Device Discovery and Development (DDDD) Committee of the American Thoracic Society (ATS). She regularly serves as an expert reviewer for scientific journals and grant funding agencies including NIH study sections, Department of Defense (DOD) study panels, National Science Foundation (NSF) study panels, AAAS, Catalent Drug Delivery Institute and international funding agencies such as the German-Israeli Foundation, German International Exchange Service (DAAD), Cochrane Airways Group of the National Health Service (London, England), Engineering and Physical Sciences Research Council (London, England), PRESTIGE Postdoc Fellowship Programme of the European Commission (Paris, France), and the Biomedical Innovation Program of the French National Research Agency (Paris, France).

In addition to serving on NSF study panels, NIH study sections, and international study panels in the European Union and Great Britain, her innovative research program continuously attracts competitive funding awards from federal sources (NIH, NSF, FDA, DOD) and the pharmaceutical industry. In addition to lecturing in the BS Pharmaceutical Sciences undergraduate, Ph.D. graduate, and Pharm.D. professional programs, Dr. Mansour leads her research labs where she trains postdoctoral scholars, visiting scholars, visiting professors, graduate students, Pharm.D. student researchers, and physician-scientist (MD/PhD) fellows. As Major Professor and mentor, her research program has successfully graduated several Ph.D.s. Her innovative research program has produced Assistant Professors employed at research universities in the United States and in the Republic of S. Korea and Senior Research Scientists employed at major pharmaceutical companies in the United States.

Dr. Mansour is an active, long-time member of several scientific organizations and elected member to honor societies, including the Sigma Xi Scientific Research Honor Society, Rho Chi Pharmaceutical Honor Society, and Golden Key International Honor Society. As a registered pharmacist for over 20 years, she earned her BS in pharmacy with honors and distinction, a PhD minor in advanced physical and interfacial chemistry (Department of Chemistry), and a PhD major in drug delivery/pharmaceutics (School of Pharmacy) from the University of Wisconsin-Madison. Also at the U.W.-Madison, she had been a Clinical Instructor for a few years. Having completed postdoctoral fellowships at the U.W.-Madison and at the University of North Carolina-Chapel Hill, she was awarded the UNC-Chapel Hill Postdoctoral Award for Research Excellence from the Office of the Vice-Chancellor, the AAPS Postdoctoral Fellow Award in Research Excellence, and the PhRMA Foundation Postdoctoral Fellowship award. As an Instructor, she served on the Graduate Faculty at UNC-Chapel Hill.

Dr. Hickey is Distinguished RTI Fellow, at the Research Triangle Institute, Emeritus Professor of Molecular Pharmaceutics of the Eshelman School of Pharmacy (2010-present, Professor 1993-2010), and Adjunct Professor Biomedical Engineering in the School of Medicine, at the University of North Carolina at Chapel Hill. He obtained Ph.D. (1984) and D.Sc. (2003) degrees in pharmaceutical sciences from Aston University, Birmingham, UK. Following postdoctoral positions, at the University of Kentucky (1984-1988) Dr. Hickey joined the faculty at the University of Illinois at Chicago (1988-1993). In 1990 he received the AAPS Young Investigator Award in Pharmaceutics and Pharmaceutical Technology. He is a Fellow of the Royal Society of Biology (2000), the American Association of Pharmaceutical Scientists (2003), the American Association for the Advancement of Science (2005) and the Royal Society of Biology (2017). He received the Research Achievement Award of the Particulate Presentations and Design Division of the Powder Technology Society of Japan (2012), the Distinguished Scientist Award of the American Association of Indian Pharmaceutical Scientists (2013); the David W Grant Award in Physical Pharmacy of the American Association of Pharmaceutical Scientists (2015); Thomas T Mercer Joint Prize for Excellence in Inhaled Medicines and Pharmaceutical Aerosols of the American Association for Aerosol Research and the International Society for Aerosols in Medicine (2017). He has published numerous papers and chapters (over 250) in the pharmaceutical and biomedical literature, one of which received the AAPS Meritorious Manuscript Award in 2001. He has edited five texts on pharmaceutical inhalation aerosols and co-authored three others on ‘Pharmaceutical Process Engineering’, pharmaceutical particulate science and ‘Pharmaco-complexity’. He holds 25 US patents on a variety of inhaler device technologies, pulmonary and oral drug delivery formulation technologies. He is founder (1997, and formerly President and CEO, 1997-2013) of Cirrus Pharmaceuticals, Inc., which was acquired by Kemwell Pharma in 2013; founder (2001, and formerly CSO, 2002-2007) of Oriel Therapeutics, Inc, which was acquired by Sandoz in 2010 and founder and CEO of Astartein, Inc. (2013-present); member of the Pharmaceutical Dosage Forms Expert Committee of the United States Pharmacopeia (USP, 2010–2015, Chair of the sub-committee on Aerosols) and formerly Chair of the Aerosols Expert Committee of the USP (2005-2010). Dr. Hickey conducts a multidisciplinary research program in the field of pulmonary drug and vaccine delivery for treatment and prevention of a variety of diseases.

About the Series

Lung Biology in Health and Disease

Learn more…

Subject Categories

BISAC Subject Codes/Headings:
MED000000
MEDICAL / General
MED071000
MEDICAL / Pharmacology
MED079000
MEDICAL / Pulmonary & Thoracic Medicine
MED084000
MEDICAL / Sports Medicine